slides · global inventory
Solution
Slide type collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 8,880
Current window 5,161-5,190
Pages 296
Rows per page 30
Slide type
5,161-5,190 of 8,880
12
The slide uses a visual process flow to explain the mechanism of action for a biotech product.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Solution1 hit
19
The slide uses bioluminescence imaging and bar charts to show immune cell activation (T cells, NK cells, MDSC, DC) in response to treatment.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations Beat · Traction1 hit
29
Includes a scientific diagram illustrating the alpha-to-beta cell reprogramming process.Genprex | Investor Presentation Deck | 39 slides · Genprex
Pitch deck Investor relations 1 hit
03
Hepion Pharmaceuticals | Results Presentation Deck | 34 slidesHepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
06
The slide uses a numbered process flow to map the stages of collagen production, highlighting specific steps where CypB is involved using red circles.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
07
The slide uses a three-part visual breakdown to map drug targets to therapeutic outcomes.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
19
The diagram uses a brain visualization to represent the integration of AI technologies into the central AI-POWR platform.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
20
Uses a funnel diagram to represent the filtering of patient data into responders and non-responders.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
31
Uses a Venn diagram to show the intersection of three core strategic pillars.Hepion Pharmaceuticals | Results Presentation Deck | 34 slides · Hepion Pharmaceuticals
Pitch deck Investor relations 1 hit
19
The diagram uses a hub-and-spoke style layout to connect internal roles and external platforms to specific creative outputs.Lanvin | Investor Presentation Deck | 58 slides · Lanvin Group
Pitch deck Investor relations 1 hit
06
The slide uses a comparison frame to illustrate the mechanism of action for the drug candidate.Larimar Therapeutics | Investor Presentation Deck | 32 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
04
The slide uses a linear process diagram to map services to business outcomes.Limbach Holdings | Investor Presentation Deck | 25 slides · Limbach
Pitch deck Investor relations Beat · SolutionLoop · Logic Chain1 hit
32
Limoneira | Investor Presentation Deck | 39 slidesLimoneira | Investor Presentation Deck | 39 slides · Limoneira
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Voice Of Customer1 hit
03
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
04
The slide illustrates the self-assembly of Phosphatidylserine (PS) and Calcium ions into a cochleate structure.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
05
The slide uses a biological process diagram to illustrate how LNCs (Lipid Nanocochleates) leverage PS to enter cells.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
06
The slide uses a comparative structure to explain two distinct biological pathways for drug delivery.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
11
The diagram uses a hub-and-spoke model to define the 'ideal' product profile.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
12
Matinas BioPharma | Investor Presentation Deck | 31 slidesMatinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Solution1 hit
21
The slide uses a chevron-based timeline to illustrate the lifecycle management strategy.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
22
Includes MIC comparison, tissue fungal burden (lung/brain), and survival curves.Matinas BioPharma | Investor Presentation Deck | 31 slides · Matinas BioPharma
Pitch deck Investor relations 1 hit
14
The slide uses a biological process diagram to explain the drug's mechanism.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
Includes a medical illustration of the intranasal drug delivery pathway to the brain.PaxMedica | Investor Presentation Deck | 24 slides · PaxMedica
Pitch deck Investor relations Beat · Solution1 hit
04
The diagram shows the signaling pathway from extracellular receptor binding to nuclear cytokine induction.Revelation Biosciences | Investor Presentation Deck | 18 slides · Revelation Biosciences
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
10
Includes a before-after comparison of medical efficacy and a market growth chart.Revelation Biosciences | Investor Presentation Deck | 18 slides · Revelation Biosciences
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
13
Includes a biological pathway diagram illustrating the mechanism of action of PHAD on TLR4 pathways.Revelation Biosciences | Investor Presentation Deck | 18 slides · Revelation Biosciences
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
15
Includes a small sketch of the test device with a 3-inch scale reference.Revelation Biosciences | Investor Presentation Deck | 18 slides · Revelation Biosciences
Pitch deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The slide outlines the market opportunity, technology, and specific applications for the SP-26 program.Silo Pharma | Investor Presentation Deck | 24 slides · Silo Pharma
Pitch deck Investor relations Beat · Solution1 hit
11
The slide outlines a specific asset (SPU-21) under a license agreement with UMB, detailing market size, technical mechanism, and research status.Silo Pharma | Investor Presentation Deck | 24 slides · Silo Pharma
Pitch deck Investor relations Beat · Solution1 hit
13
The slide outlines a specific pharmaceutical asset (SPC-15) and its market context.Silo Pharma | Investor Presentation Deck | 24 slides · Silo Pharma
Pitch deck Investor relations Beat · SolutionLoop · Voice Of Customer1 hit